What to Expect after an Inspection: 483s, Responses and Beyond

During this webinar, FDA provided an overview of what to expect after a compounding inspection. FDA discussed the intent of an FDA Form 483, ‘Inspectional Observation,’ compounding inspection closeout meetings, post-inspection expectations and regulatory responses, and provided a few examples to help explain how best to respond to an FDA Form 483 observation after a compounding inspection.
Timestamps
07:07 - Rebecca Asente, MS, RD - What to Expect After an Inspection
31:02 - Jennifer DelValleOrtiz, MS - Discussion of Examples
42:58 - Q&A Discussion Panel
59:16 - FDA Compounding Quality Center of Excellence
Speakers:
Rebecca Asente, MS, RD
Compliance Officer
Office of Pharmaceutical Quality Operations (OPQO)
Office of Regulatory Affairs (ORA) | US FDA
Jennifer DelValleOrtiz, MS
Supervisory Consumer Safety Officer
Division of Compounding I (DC1)
Office of Compounding Quality & Compliance (OCQC)
Office of Compliance (OC)
Center for Drug Evaluation and Research (CDER) | US FDA
Jill Hammond
Captain, US Public Health Service
Program Manager
Office of Compounding Quality & Compliance (OCQC)
Office of Compliance (OC)
Center for Drug Evaluation and Research (CDER)| US FDA
Panelists:
Rebecca Asente and Jennifer DelValleOrtiz
Learn more at: www.fda.gov/dr...
-----------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - www.fda.gov/cd...
SBIA Listserv - public.govdeli...
SBIA 2022 Playlist - • 2022 CDER Small Busine...
SBIA LinkedIn -  / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cd...
Twitter -  / fda_drug_info
Email - [e-mail]
Phone - [phone] I [phone]